Want to see IOVA full AI Analyst Report?
IOVA Stock Chart & Stats
$4.99
-$0.14(-2.73%)
At close: 4:00 PM EDT
$4.99
-$0.14(-2.73%)
Day’s Range― - ―
52-Week Range$1.76 - $6.92
Previous CloseN/A
Volume9.43M
Average Volume (3M)15.29M
Market Cap
$1.82B
Enterprise Value$1.62K
Total Cash (Recent Filing)$297.67M
Total Debt (Recent Filing)$46.00M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Nov 05, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.70
Shares Outstanding446,502,400
10 Day Avg. Volume19,202,152
30 Day Avg. Volume15,288,864
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.40
Price to Sales (P/S)3.70
P/FCF Ratio-2.90
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.83Price Target Upside77.02% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.57
Revenue Forecast (FY)$362.40M
Bulls Say, Bears Say
Bulls Say
Commercial TractionSustained, one-time-per-patient AMTAGVI sales drove clear revenue acceleration (Q2 $99.3M; Amtagvi ~$91M, +68% YoY). Durable commercial adoption (>95 ATCs, >50 treated patients/month) indicates scalable demand and a repeatable revenue engine tied to clinical eligibility and treatment center coverage.
Manufacturing & OpsFull in-house manufacturing with ≤31 day turnaround and active cost/AI initiatives creates a durable competitive advantage: faster throughput, better yield control, and lower COGS potential. That operational control supports margin expansion and capacity to commercialize lifileucel across additional indications.
Balance Sheet StrengthA low-leverage balance sheet and roughly $304M cash (runway into H2 2028 per company) provide multi-quarter funding headroom to scale commercial operations and complete registrational trials. Capital flexibility reduces near-term financing pressure while management executes commercialization and pipeline milestones.
Bears Say
Negative Cash FlowOperating and free cash flow remain negative despite improvement, meaning the business still depends on existing cash, potential financings, or improved margins to fund growth. Persistent cash burn can force dilution or constrain investment in trials and commercial expansion if revenue growth stalls.
Profitability Still ElusiveAlthough gross margins expanded and losses narrowed, the company remains materially unprofitable on an operating and net basis. Without sustained positive operating margins, long-term self-funded growth is unlikely, leaving performance contingent on continued margin improvement and scaling unit economics.
Scale & Market Access RisksInternational commercialization faces pending approvals and reimbursement workstreams, while new authorized treatment centers take months to ramp to steady volumes. These structural adoption and access frictions limit predictable global volume growth and delay realization of addressable-market potential.
Iovance Biotherapeutics News
IOVA FAQ
What was Iovance Biotherapeutics’s price range in the past 12 months?
Iovance Biotherapeutics lowest stock price was $1.76 and its highest was $6.92 in the past 12 months.
What is Iovance Biotherapeutics’s market cap?
Iovance Biotherapeutics’s market cap is $1.82B.
When is Iovance Biotherapeutics’s upcoming earnings report date?
Iovance Biotherapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 87 days.
How were Iovance Biotherapeutics’s earnings last quarter?
Iovance Biotherapeutics released its earnings results on Aug 06, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.133 by $0.023.
Is Iovance Biotherapeutics overvalued?
According to Wall Street analysts Iovance Biotherapeutics’s price is currently Undervalued.
Does Iovance Biotherapeutics pay dividends?
Iovance Biotherapeutics does not currently pay dividends.
What is Iovance Biotherapeutics’s EPS estimate?
Iovance Biotherapeutics’s EPS estimate is -0.09.
How many shares outstanding does Iovance Biotherapeutics have?
Iovance Biotherapeutics has 446,502,400 shares outstanding.
What happened to Iovance Biotherapeutics’s price movement after its last earnings report?
Iovance Biotherapeutics reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.133. Following the earnings report the stock price went up 43.088%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics?
Currently, no hedge funds are holding shares in IOVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iovance Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.83 (77.02% Upside)
$8.83 (77.02% Upside)
Blogger Sentiment
Bullish
IOVA Sentiment 92%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 571.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.89%
Trailing 12-Months
Company Description
Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
IOVA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial execution and meaningful operational progress: record revenue ($99.3M), a best-ever 56% gross margin, accelerating Amtagvi uptake (~$91M revenue, +51% sequential and +68% YoY), expanding ATC footprint (>95 ATCs), and important pipeline/regulatory milestones (LUN-202 near-complete enrollment, SARATOGA Fast Track). Key challenges include limited sample sizes in some early efficacy readouts, pending international reimbursement/approvals, near-term guidance review, and the need to sustain funding for continued scale and trials. On balance, the positive commercial momentum, margin expansion, pipeline advancement, and disciplined cost management significantly outweigh the near-term uncertainties.View all IOVA earnings summariesIOVA Stock 12 Month Forecast
Average Price Target
$8.83
▲(77.02% Upside)
Technical Analysis
Nektar Therapeutics
―
Arcus Biosciences
―
Immatics
―
Nuvation Bio
―
Immunocore Holdings
―
Ownership Overview
0.32% Insiders
12.27% Mutual Funds
1.53% Other Institutional Investors
68.00% Public Companies and Individual Investors